drugset / Trial / NCT06340204
Weekly Irinotecan Liposomes in Recurrent or Refractory Ewing Sarcoma
Phase 1
Recruiting
44 enrolled
Peking University People's Hospital
Peking University Shougang Hospital · collabShandong Cancer Hospital and Institute · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The investigators explored the safety and activity of weekly irinotecan liposomes in patients with relapsed and metastatic Ewing Sarcoma.
Timeline
- Start
- 2024-03-25
- Primary completion
- 2026-03-25
- Completion
- 2026-12-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Irinotecan | Small molecule | — | — |